Cutaneous Reaction SARS-CoV-2 Vaccination: A Cross-Sectional Study

Background: Following the COVID-19 virus pandemic, the globe has begun immunization programmers using a variety of vaccines. Objective: Our study aimed to recognize dermatological responses emerging in response to the COVID-19 vaccines delivered in Egypt and to ascertain their clinical characteristics and potential contributing variables. Materials and method: Individuals over the age of 18 who experienced dermatological reactions after receivingthe COVID-19 vaccine were included in the study between December 2021 andDecember 2022. The evaluation used anelectronic survey on Google forms that were created by the research team and had itsvalidity and reliability evaluated by five dermatology-specific doctors. A routinesurvey that questioned questions about age, gender, place of residence, smoking,medical history, allergy, number of doses and when cutaneous reactions started afterimmunization. According to the severity of the symptoms following the vaccination,dermatological reactions were grouped. Result: The study comprised a total of 1000 patients, of which 413 men (41.3%) and 587women (58.7%). It was found that COVID arm (25.2%), pityriasis rosea (13.6%), vasculitis (11.4%), and lichen planus (9.2%) were the dermatological conditions and reactions that arose most commonly following immunization. After delivery of the vaccine, the rate of dermatological reactions was 63.8% (with 41.6% reported mild symptoms, 15.6% reported moderate symptoms, and 6.6% reported severe symptoms). The patients who received the immunizations experienced a statistically significantly increased number of responses (p = 0.001). Conclusion: The most common reactions in our sample were COVID arm, pityriasis rosea, and Vasculitis.